Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 1-2/2006

01-06-2006

Wnt signaling and osteoblastogenesis

Authors: Peter V. N. Bodine, Barry S. Komm

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1-2/2006

Login to get access

Abstract

Wnts are a large family of growth factors that mediate fundamental biological processes like embryogenesis, organogenesis and tumorigenesis. These proteins bind to a membrane receptor complex comprised of a frizzled (FZD) G-protein-coupled receptor (GPCRs) and a low-density lipoprotein (LDL) receptor-related protein (LRP). The formation of this ligand-receptor complex initiates a number of intracellular signaling cascades that includes the canonical/β-catenin pathway, as well as several GPCR-mediated noncanonical pathways. In recent years, canonical Wnt signaling has been shown to play a substantial role in the control of bone formation. Clinical investigations have found that mutations in LRP-5 are associated with bone mineral density and fractures. For example, loss-of-function mutations in LRP-5 cause osteoporosis pseudoglioma syndrome, while gain-of-function mutations lead to high bone mass phenotypes. Studies of knockout and transgenic mouse models for Wnt pathway components like Wnt-10b, LRP-5/6, secreted frizzled-related protein-1, dickkopf-2, Axin-2 and β-catenin have demonstrated that canonical signaling modulates most aspects of osteoblast physiology including proliferation, differentiation, bone matrix formation/mineralization and apoptosis as well as coupling to osteoclastogenesis and bone resorption. Future studies in this rapidly growing area of research should focus on elucidating Wnt/FZD specificity in the control of bone cell function, the role of noncanonical pathways in skeletal remodeling, and direct effects of Wnts on cells of the osteoclast lineage.
Literature
1.
go back to reference Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998;14:59–88.PubMedCrossRef Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998;14:59–88.PubMedCrossRef
2.
3.
go back to reference Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781–810.PubMedCrossRef Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781–810.PubMedCrossRef
4.
go back to reference Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691–701.PubMedCrossRef Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691–701.PubMedCrossRef
5.
go back to reference Sharpe C, Lawrence N, Martinez Arias A. Wnt signalling: a theme with nuclear variations. Bioessays 2001;23:311–8.PubMedCrossRef Sharpe C, Lawrence N, Martinez Arias A. Wnt signalling: a theme with nuclear variations. Bioessays 2001;23:311–8.PubMedCrossRef
6.
go back to reference Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000;16:279–83.PubMedCrossRef Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000;16:279–83.PubMedCrossRef
7.
go back to reference Chen AE, Ginty DD, Fan C-M. Protein kinase A signaling via CREB control myogenesis induced by Wnt proteins. Nature 2005;433:317–22.PubMedCrossRef Chen AE, Ginty DD, Fan C-M. Protein kinase A signaling via CREB control myogenesis induced by Wnt proteins. Nature 2005;433:317–22.PubMedCrossRef
9.
11.
go back to reference Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002;24:811–20.PubMedCrossRef Jones SE, Jomary C. Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 2002;24:811–20.PubMedCrossRef
12.
go back to reference Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627–34.PubMedCrossRef Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627–34.PubMedCrossRef
13.
go back to reference Rawadi G, Roman-Roman S. Wnt signaling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 2005;9:1063–77.PubMedCrossRef Rawadi G, Roman-Roman S. Wnt signaling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 2005;9:1063–77.PubMedCrossRef
14.
go back to reference van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowick CWGM. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319–27.PubMedCrossRef van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowick CWGM. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319–27.PubMedCrossRef
15.
go back to reference Bodine PV, Komm BS. Tissue culture models for studies of hormone and vitamin action in bone cells. Vitam Horm 2002;64:101–51.PubMedCrossRef Bodine PV, Komm BS. Tissue culture models for studies of hormone and vitamin action in bone cells. Vitam Horm 2002;64:101–51.PubMedCrossRef
16.
go back to reference Lian JB, Stein GS, Aubin JE. Bone formation: maturation and functional activities of osteoblast lineage cells. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, District of Columbia: American Society for Bone and Mineral Research; 2003. pp. 13–28. Lian JB, Stein GS, Aubin JE. Bone formation: maturation and functional activities of osteoblast lineage cells. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, District of Columbia: American Society for Bone and Mineral Research; 2003. pp. 13–28.
17.
go back to reference Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19–39.PubMedCrossRef Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19–39.PubMedCrossRef
18.
go back to reference Bodine PVN, Robinson JA, Bhat RA, Billiard J, Bex FJ, Komm BS. The role of Wnt signaling in bone and mineral metabolism. Clinical Reviews in Bone and Mineral Metabolism 2006;4:73–96. Bodine PVN, Robinson JA, Bhat RA, Billiard J, Bex FJ, Komm BS. The role of Wnt signaling in bone and mineral metabolism. Clinical Reviews in Bone and Mineral Metabolism 2006;4:73–96.
19.
go back to reference Koay MA, Brown MA. Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol Med 2005;11:129–37.PubMedCrossRef Koay MA, Brown MA. Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol Med 2005;11:129–37.PubMedCrossRef
20.
go back to reference Ferrari SL, Deutsch S, Antonarakis SE. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass. Curr Opin Lipidol 2005;16:207–14.PubMedCrossRef Ferrari SL, Deutsch S, Antonarakis SE. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass. Curr Opin Lipidol 2005;16:207–14.PubMedCrossRef
21.
go back to reference Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA, 2nd, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002;157:303–14.PubMedCrossRef Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA, 2nd, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002;157:303–14.PubMedCrossRef
22.
go back to reference Kharode YP, Green PD, Marzolf JT, Zhao W, Askew R, Yaworsky P, et al. Alteration in bone density of mice due to heterozygous inactivation of LRP6. J Bone Miner Res 2003;18:S60. Kharode YP, Green PD, Marzolf JT, Zhao W, Askew R, Yaworsky P, et al. Alteration in bone density of mice due to heterozygous inactivation of LRP6. J Bone Miner Res 2003;18:S60.
23.
go back to reference Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, et al. Decreased BMD and limb deformities in mice carrying mutations in both LRP5 and LRP6. J Bone Miner Res 2004;19:2033–40.PubMedCrossRef Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, et al. Decreased BMD and limb deformities in mice carrying mutations in both LRP5 and LRP6. J Bone Miner Res 2004;19:2033–40.PubMedCrossRef
24.
go back to reference Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003;18:960–74.PubMedCrossRef Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003;18:960–74.PubMedCrossRef
25.
go back to reference Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, Haynatzki GR, et al. Bone biomechanical properties in LRP5 mutant mice. Bone 2004;35:162–9.PubMedCrossRef Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, Haynatzki GR, et al. Bone biomechanical properties in LRP5 mutant mice. Bone 2004;35:162–9.PubMedCrossRef
26.
go back to reference Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005;132:49–60.PubMedCrossRef Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005;132:49–60.PubMedCrossRef
27.
go back to reference Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Developmental Cell 2005;8:727–38.PubMedCrossRef Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Developmental Cell 2005;8:727–38.PubMedCrossRef
28.
go back to reference Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 2005;8:739–50.PubMedCrossRef Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 2005;8:739–50.PubMedCrossRef
29.
go back to reference Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005;280:21162–8.PubMedCrossRef Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005;280:21162–8.PubMedCrossRef
30.
go back to reference Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005;8:751–64.PubMedCrossRef Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005;8:751–64.PubMedCrossRef
31.
go back to reference Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 2005;36:585–98.PubMedCrossRef Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 2005;36:585–98.PubMedCrossRef
32.
go back to reference Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, et al. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development 2005;132:1995–2005.PubMedCrossRef Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, et al. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development 2005;132:1995–2005.PubMedCrossRef
33.
go back to reference Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005;37:945–52.PubMedCrossRef Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005;37:945–52.PubMedCrossRef
34.
go back to reference Kang S, Bajnok L, Longo KA, Petersen RK, Hansen JB, Kristiansen K, et al. Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol Cell Biol 2004;25:1272–82.CrossRef Kang S, Bajnok L, Longo KA, Petersen RK, Hansen JB, Kristiansen K, et al. Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol Cell Biol 2004;25:1272–82.CrossRef
35.
go back to reference Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, Lucas PC, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 2004;279:35503–9.PubMedCrossRef Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, Lucas PC, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 2004;279:35503–9.PubMedCrossRef
36.
go back to reference Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324–9.PubMedCrossRef Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324–9.PubMedCrossRef
37.
go back to reference Bodine PVN, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, Mangine A, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005;96:1212–30.PubMedCrossRef Bodine PVN, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, Mangine A, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005;96:1212–30.PubMedCrossRef
38.
go back to reference Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004;18:1222–37.PubMedCrossRef Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004;18:1222–37.PubMedCrossRef
39.
go back to reference Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005;280:41342–51.PubMedCrossRef Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005;280:41342–51.PubMedCrossRef
40.
go back to reference Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005;280:33132–40.PubMedCrossRef Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005;280:33132–40.PubMedCrossRef
41.
go back to reference Lian JB, Trevant B, Symons J, Komm BS, Bodine PVN, Stein GS. The SFRP-1 gene, a Wnt antagonist, is expressed during embryonic development in bone and cartilage. J Bone Miner Res 2002;17:S405. Lian JB, Trevant B, Symons J, Komm BS, Bodine PVN, Stein GS. The SFRP-1 gene, a Wnt antagonist, is expressed during embryonic development in bone and cartilage. J Bone Miner Res 2002;17:S405.
42.
go back to reference Trevant B, Symons J, Gaur T, Hussain S, Komm BS, Bodine PVN, et al. Normal embryonic mouse development does not require sFRP-1, a Wnt antagonist expressed in soft tissues and the skeleton. Submitted for publication, 2005. Trevant B, Symons J, Gaur T, Hussain S, Komm BS, Bodine PVN, et al. Normal embryonic mouse development does not require sFRP-1, a Wnt antagonist expressed in soft tissues and the skeleton. Submitted for publication, 2005.
43.
go back to reference Gaur T, Rich L, Lengner CJ, Hussain S, Trevant B, Ayers A, et al. Secreted frizzled-related protein-1 regulates Wnt Signaling for BMP2 induced chondrocyte differentiation. J Cell Physiol 2006;208:87–96. Gaur T, Rich L, Lengner CJ, Hussain S, Trevant B, Ayers A, et al. Secreted frizzled-related protein-1 regulates Wnt Signaling for BMP2 induced chondrocyte differentiation. J Cell Physiol 2006;208:87–96.
Metadata
Title
Wnt signaling and osteoblastogenesis
Authors
Peter V. N. Bodine
Barry S. Komm
Publication date
01-06-2006
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 1-2/2006
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-006-9002-4

Other articles of this Issue 1-2/2006

Reviews in Endocrine and Metabolic Disorders 1-2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.